Bartholomew K, Sloan J P
Accident and Emergency Department, Leeds General Infirmary, U.K.
Arch Emerg Med. 1990 Sep;7(3):189-95. doi: 10.1136/emj.7.3.189.
Prilocaine has become the agent of choice for Bier's block (or intravenous regional anaesthesia--IVRA), since 1983 when the product licence of bupivacaine was withdrawn for this purpose owing to fatal or serious complications. No serious complications have been documented in the literature relating to prilocaine in IVRA and we have conducted a survey within the U.K. which indicates that about 45,000 Bier's blocks have been carried out with prilocaine without convulsion, arrhythmia or fatality. This includes cases of accidental cuff deflation or even failure to inflate the cuff, resulting in bolus doses to the circulation. Prilocaine has now been in use since 1964 and the Committee for Safety of Medicines has no deaths on record over a 25-year period. (This includes other types of regional anaesthesia). We suggest that intravenous regional anaesthesia using prilocaine is a safe technique. It is highly unlikely that fatalities will occur, provided present guidelines are adhered to. We can find no reason to limit its use to trained anaesthetists only, but would recommend that a strict protocol is adhered to.
自1983年以来,丙胺卡因已成为用于 Bier 阻滞(或静脉区域麻醉——IVRA)的首选药物。当时,由于致命或严重并发症,布比卡因的该用途产品许可证被撤回。文献中未记载与IVRA中丙胺卡因相关的严重并发症,并且我们在英国进行了一项调查,结果表明约45,000例使用丙胺卡因的Bier阻滞未出现惊厥、心律失常或死亡。这包括意外松开袖带甚至未给袖带充气,导致大剂量药物进入循环系统的情况。丙胺卡因自1964年开始使用,药品安全委员会在25年期间没有相关死亡记录。(这包括其他类型的区域麻醉)。我们认为使用丙胺卡因进行静脉区域麻醉是一项安全的技术。只要遵守现行指南,发生死亡的可能性极小。我们找不到理由仅将其使用限制于受过培训的麻醉医生,但建议严格遵守相关规程。